ClinicalTrials.gg
CompletedNCT04397276Updated Feb 17, 2026

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

A Phase 1 interventional study of JNJ-70218902 in Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 7 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.

Read the detailed description

JNJ-70218902, the investigational drug, has been shown in pre-clinical studies to work by attaching to cancer cells and activating immune cells to kill these cancer cells. This study will be conducted in 2 parts: dose escalation (Part 1) and dose expansion (Part 2) and will enroll adult men with Metastatic Castration-Resistant Prostate Cancer (MCRPC). Study evaluations will include preliminary clinical efficacy, safety, pharmacokinetics, biomarkers and immunogenicity evaluations. This study is divided into 3 periods: screening, treatment and post-treatment. The total duration of the study will be 2.5 years approximately.

02

Conditions studied

  • Neoplasms

Keywords

  • metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Prostate Cancer
03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 82 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histology: castration-resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma. Adenocarcinoma with small-cell or neuroendocrine features is allowed
  • Measurable or evaluable disease
  • Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy
  • If the participant is receiving treatment with gonadotropin-releasing hormone agonists or antagonist analogs (GnRH), this therapy must have been initiated prior to first dose of study drug and must be continued throughout the study
  • (ECOG) performance status grade of 0 or 1
  • Adequate organs functions

Exclusion criteria

Exclusion Criteria:

  • Known
  • Concurrent use of any other anticancer treatment or agent for the treatment of advanced disease
  • Toxicities related to prior anticancer treatments have not returned to Grade less than or equal to (\<=) 1 or baseline, except for alopecia and vitiligo
  • Solid organ or bone marrow transplantation
  • Known allergies, , or intolerance to JNJ-70218902 or its
  • Certain comorbidities
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Escalation

    Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.

    Drug: JNJ-70218902

  • Experimental
    Part 2: Dose Expansion

    Participants with mCRPC will receive JNJ-70218902 at the RP2D determined in Part 1.

    Drug: JNJ-70218902

Interventions

  • DrugJNJ-70218902

    JNJ-70218902 will be administered.

06

What researchers measure

Primary outcomes

  1. Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 2.5 years

  2. Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)

    Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

    Time frame: Up to 21 days

  3. Part 1 and Part 2: Number of Participants with AEs by Severity

    Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 with the exception of cytokine release syndrome (CRS), which will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

    Time frame: Up to 2.5 years

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of JNJ-70218902

    Cmax is the maximum observed serum concentration of JNJ-70218902.

    Time frame: Up to 2.5 years

  2. Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-70218902

    Tmax is defined as time to reach maximum observed serum concentration.

    Time frame: Up to 2.5 years

  3. Area Under the Serum Concentration-time Curve From t1 to t2 Time (AUC[t1-t2]) of JNJ-70218902

    AUC(t1-t2) is defined as the area under the serum concentration-time curve from time t1 to t2.

    Time frame: Up to 2.5 years

  4. Area Under the Concentration-time Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-70218902

    AUCtau is the measure of the serum drug concentration from time zero to end of dosing interval.

    Time frame: Up to 2.5 years

  5. Minimum Observed Serum Concentration (Cmin) of JNJ-70218902

    Cmin is the minimum observed serum concentration of JNJ-70218902.

    Time frame: Up to 2.5 years

  6. Accumulation Ratio (RA) of JNJ-70218902

    Accumulation Ratio (RA) is calculated as area under the plasma concentration-time curve from time zero to 24 hours (AUC \[0-24\]) value at steady state divided by AUC (0-24) value after first dose.

    Time frame: Up to 2.5 years

  7. Systemic Cytokine Concentrations

    Cytokines concentration will be measured for biomarker assessment.

    Time frame: Up to 2.5 years

  8. Serum Prostate Specific Antigen (PSA) Concentration

    Serum prostate specific antigen (PSA) concentration will be measured.

    Time frame: Up to 2.5 years

  9. Number of Participants With Anti-JNJ-70218902 Antibodies

    Number of participants with anti-JNJ-70218902 antibodies will be assessed.

    Time frame: Up to 2.5 years

  10. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have a Partial Response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 without evidence of bone progression according to Prostate Cancer Working Group 3 (PCWG3).

    Time frame: Up to 2.5 years

  11. Duration of Response (DOR)

    Duration of response (DOR) will be calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 2.5 years

07

Study locations

7 sites
  • BC Cancer Agency - Vancouver BC
    Vancouver, British Columbia V5Z 4E6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Hosp Univ Vall D Hebron
    Barcelona, 08035, Spain
  • Hosp Univ Fund Jimenez Diaz
    Madrid, 28040, Spain
  • Hosp Univ Hm Sanchinarro
    Madrid, 28050, Spain
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Sep 2025, 62 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 62 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2020
First posted
May 21, 2020
StartActual
Jul 10, 2020
Primary completionActual
Sep 16, 2025
CompletionActual
Sep 16, 2025
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04397276
Responsible party
Sponsor
First posted
May 21, 2020
Start date
Jul 10, 2020
Primary completion
Sep 16, 2025
Completion
Sep 16, 2025
Last update
Feb 17, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion